ACADIA Pharmaceuticals
ACAD
#3675
Rank
NZ$4.96 B
Marketcap
$29.86
Share price
0.84%
Change (1 day)
-40.13%
Change (1 year)

P/E ratio for ACADIA Pharmaceuticals (ACAD)

P/E ratio as of December 2024 (TTM): -18.3

According to ACADIA Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -18.337. At the end of 2022 the company had a P/E ratio of -11.9.

P/E ratio history for ACADIA Pharmaceuticals from 2004 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-11.9-46.55%
2021-22.2-25.16%
2020-29.711.08%
2019-26.7222.44%
2018-8.29-35.28%
2017-12.83.96%
2016-12.3-43.65%
2015-21.9-35.25%
2014-33.8-40.53%
2013-56.8351.92%
2012-12.6412.01%
2011-2.45-181.82%
20103.00-370.45%
2009-1.11111.99%
2008-0.5233-92.44%
2007-6.9226.73%
2006-5.46-14.64%
2005-6.4070.38%
2004-3.75

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
17.7-196.55%๐Ÿ‡บ๐Ÿ‡ธ USA
14.2-177.29%๐Ÿ‡บ๐Ÿ‡ธ USA
141-871.18%๐Ÿ‡บ๐Ÿ‡ธ USA
10.3-155.93%๐Ÿ‡บ๐Ÿ‡ธ USA
14.4-178.75%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.